In recent trading, Lexicon Pharmaceuticals Inc (LXRX) stock price has shown some volatility, fluctuating -33.33% over the last five trades and -22.62% over the past 30 trades. This represents a ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon management including Mike Exton, Lexicon’s chief executive ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.44% of ...

THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference.

An FDA advisory committee voted Thursday that it didn’t believe the benefits of Lexicon's (LXRX) diabetes drug sotagliflozin ...

Lexicon Pharmaceuticals LXRX has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

with a majority of members saying the data provided by sponsor Lexicon Pharmaceuticals contained too much uncertainty. "I ...

Pharmaceuticals announced it will present data from two studies related to LX9851, its investigational compound for obesity and ...

While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...